Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)28.41m
- Net income in EUR-19.95m
- Incorporated2002
- Employees145.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Industri Jamu dn Frms Sd Mncl Tbk PT | 201.32m | 60.65m | 796.01m | 3.56k | 13.05 | 4.58 | 12.01 | 3.95 | 40.62 | 40.62 | 134.92 | 115.65 | 1.05 | 3.17 | 5.99 | 1,128,331,000.00 | 31.51 | 27.62 | 33.97 | 31.69 | 58.69 | 56.70 | 30.13 | 28.98 | 5.29 | -- | 0.0005 | 97.08 | 9.90 | 5.02 | 23.18 | 7.71 | -19.12 | 9.91 |
| Jeena Sikho Lifecare Ltd | -930.45m | -930.45m | 807.68m | 3.76k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.29 | -- | 40.74 | -- | 92.07 | -- | 16.78 | -- | -- | -- | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 106.26m | 6.97m | 817.40m | 668.00 | 119.92 | 2.10 | -- | 7.69 | 0.3515 | 0.3515 | 5.55 | 20.06 | 0.2166 | 1.58 | 2.86 | 1,304,353.00 | 0.8033 | 3.82 | 0.9658 | 4.45 | 89.11 | 88.68 | 3.71 | 16.16 | 2.98 | -- | 0.0745 | 31.72 | -10.28 | -4.99 | -71.94 | -30.80 | 40.67 | -- |
| Theravance Biopharma Inc | 67.68m | 24.72m | 833.83m | 97.00 | 34.71 | 4.25 | 31.93 | 12.32 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Shanghai OPM Biosciences Co Ltd | 43.04m | 5.27m | 834.82m | 328.00 | 140.33 | 2.84 | -- | 19.40 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Cronos Group Inc | 111.51m | 30.41m | 835.61m | 626.00 | 28.83 | 0.9228 | 19.17 | 7.49 | 0.1233 | 0.1233 | 0.464 | 3.85 | 0.112 | 1.57 | 5.56 | -- | 3.51 | -8.99 | 3.81 | -9.77 | 43.35 | 2.22 | 31.36 | -159.15 | 21.28 | -- | 0.00 | -- | 34.82 | 37.71 | 158.81 | -48.79 | -19.52 | -- |
| Medincell SA | 28.41m | -19.95m | 839.01m | 145.00 | -- | -- | -- | 29.54 | -0.6143 | -0.6143 | 0.8982 | -0.9254 | 0.4258 | -- | 28.18 | 202,907.10 | -29.90 | -51.18 | -50.21 | -133.26 | 56.60 | 82.68 | -70.22 | -210.68 | -- | -0.9935 | 2.11 | -- | 181.43 | 54.88 | 26.36 | -- | 13.30 | -- |
| Tchaikapharma High Quality Medicines AD | 30.71m | 3.41m | 854.27m | 209.00 | 261.44 | 15.19 | 172.52 | 27.82 | 0.0356 | 0.0356 | 0.3202 | 0.6125 | 0.4682 | 2.46 | 0.9284 | 148,346.60 | 5.21 | 2.11 | 5.87 | 2.44 | 35.06 | 29.47 | 11.12 | 5.56 | 4.90 | 174.93 | 0.0926 | -- | 9.72 | 8.94 | 32.14 | 11.82 | -- | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 86.79m | -7.64m | 862.51m | 925.00 | -- | 3.96 | -- | 9.94 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Shanghai Haixin Group Co Ltd | 96.11m | 19.06m | 863.32m | 715.00 | 64.45 | 2.16 | -- | 8.98 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
| Sanofi India Ltd | 179.81m | 33.15m | 865.04m | 991.00 | 26.09 | -- | 23.61 | 4.81 | 154.71 | 154.71 | 839.09 | -- | -- | -- | -- | 19,500,500.00 | -- | 22.31 | -- | 31.44 | 51.42 | 54.10 | 18.44 | 21.53 | -- | 321.27 | -- | 132.73 | 0.8567 | -8.10 | -13.96 | -5.41 | -13.65 | 1.99 |
| China Shineway Pharmaceutical Group Ltd | 408.29m | 101.12m | 865.66m | 2.87k | 7.82 | 0.9079 | 10.30 | 2.12 | 1.24 | 1.24 | 5.01 | 10.70 | 0.3299 | 1.15 | 3.81 | 1,176,221.00 | 8.17 | 8.29 | 10.75 | 10.38 | 73.36 | 74.83 | 24.77 | 18.67 | 3.39 | -- | 0.0419 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
| Genomma Lab Internacional SAB de CV | 892.95m | 84.19m | 876.83m | 1.71k | 10.51 | 1.59 | 8.42 | 0.982 | 1.71 | 1.15 | 18.06 | 11.27 | 0.7721 | 3.09 | 3.71 | 11,333,190.00 | 7.28 | 6.85 | 10.26 | 10.26 | 63.30 | 61.94 | 9.43 | 8.93 | 1.54 | 3.88 | 0.4025 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
Data as of Feb 13 2026. Currency figures normalised to Medincell SA's reporting currency: Euro EUR
26.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2025 | 2.46m | 7.37% |
| Polar Capital LLPas of 22 Jan 2026 | 1.67m | 5.01% |
| Adage Capital Management LPas of 30 Jun 2025 | 1.26m | 3.78% |
| Syquant Capital SASas of 30 Jun 2025 | 923.76k | 2.77% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 755.32k | 2.27% |
| CPR Asset Management SAas of 31 Dec 2025 | 554.14k | 1.66% |
| AXA Investment Managers (Paris) SAas of 30 Jan 2026 | 363.21k | 1.09% |
| Saint Olive Gestion SNCas of 31 Dec 2025 | 339.05k | 1.02% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 335.30k | 1.01% |
| Montpensier Arbevel SASas of 30 Jun 2025 | 298.30k | 0.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
